Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2006-04-17
2008-08-12
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S130100, C435S345000
Reexamination Certificate
active
07410642
ABSTRACT:
Compositions that bind viral proteins that are specifically expressed during the latent stage of the viral life cycle are disclosed. These compositions bind the latent viral proteins while the viral proteins are expressed in their cellular host, and provide a means for targeting cells that harbor latent virus. In a preferred embodiment the compositions are antibodies which bind the extracellular region of the latent viral protein, most preferably LMP-2A, an EBV latent protein, which are conjugated to a diagnostic or cytotoxic agent or immobilized to a solid support for removal of the infected cells. These antibodies are capable of distinguishing cells expressing EBV DNA from cells which are not expressing EBV DNA. Compositions that can be used to elicit production of these antibodies, or as a vaccine, are also disclosed. Methods for generating diagnostic or cytotoxic reagents and vaccines based on the viral epitopes that identify cells harboring latent virus are also disclosed. The antibody conjugates can be used in diagnostic assays to identify cells expressing latent viral protein and people who are harboring latent viral particles. The antibody conjugates can also be used to remove the infected cells or to kill the infected the cells. Alternatively, or in addition, the viral proteins or portions thereof can be used as a vaccine to induce an immune reaction by the host to kill the infected cells. These methods can be used to detect or treat patients harboring latent viruses like EBV and who are at risk of developing a disease such as an autoimmune disease like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
REFERENCES:
patent: 4244946 (1981-01-01), Rivier et al.
patent: 4305872 (1981-12-01), Johnston et al.
patent: 4316891 (1982-02-01), Guillemin et al.
patent: 4675382 (1987-06-01), Murphy
patent: 4792525 (1988-12-01), Ruoslahti et al.
patent: 5637454 (1997-06-01), Harley
patent: 5861240 (1999-01-01), Ganem et al.
patent: 5906820 (1999-05-01), Bacha
patent: WO 98/30586 (1998-07-01), None
patent: WO 99/02550 (1999-01-01), None
Rowe et al. Journal of General Virology, 1987, vol. 68, pp. 1575-1586.
Meij et al. The Journal of Infectious Diseases, May 1999, vol. 179, pp. 1108-1115.
Adelstein et al., “Radiobiologic implications of the microscopic distribution of energy from radionuclides,”Nucl. Med. Biol., 14:165-169, 1987.
Alford, Antiviral agents and viral diseases of man, 2nded. Raven Press: New York, pp. 433-486, 1984.
Alspaugh et al., “Elevated levels of antibodies to Epstein-Barr virus antigens in sera and synovial fluids of patients with rheumatoid arthritis,”J. Clin. Invest., 67:1134-1140, 1981.
Alspaugh et al., “Serum antibody in rheumatoid arthritis reactive with a cell-associated antigen. Demonstration by precipitation and immunofluorescence,”Arthr. Rheum., 19:711-719, 1976.
Ashley et al., “Detection of asymptomatic herpes simples virus infections after vaccination,”J. Virol., 61:253-258, 1987.
Babcock et al., “Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients,”J. Exp. Med., 190:567-576, 1999.
Barnes,J. Pharma Weekly, 1:11, 1995.
Bell et al., “Antibody to rheumatoid arthritis associated nuclear antigen (RANA) in familial rheumatoid arthritis,”J. Rheumatol., 11:277-281, 1984.
Bray et al., “Antibodies against Epstein-Barr Nuclear Antigen (EBNA) in Multiple Sclerosis CSF, and two pentapeptide sequence identities between EBNA and Myelin basic protein,”Arch. Neur., 42:1798-1804, 1992.
Bray et al., “Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF< and two pentapeptide sequences identities between EBNA and myelin basic protein,”Arch. Neur., 40:406-408, 1983.
Browning et al., “Studies on the differing effects of tumor necrosis factor and lymphotoxin on the growth of several human tumor lines,”J. Immunol., 143:1859-1867, 1989.
Calderwood et al., “Nucleotide sequence of the Shiga-like toxin genes ofEscherichia coli,” Proc. Natl. Acad. Sci. USA, 84:4364-4368, 1987.
Catalano et al., “Antibodies of Epstein-Barr virus-determined antigens in normal subjects and in patients with seropositive rheumatoid arthritis,”Proc. Natl. Acad. Sci. USA, 76:5825-5828, 1979.
Chen et al., “Production of mulitmeric forms of CD4 through sugar-based cross-linking strategy,”J. Biol. Chem., 266:18237-18243, 1994.
Colombatti et al., Cloned fragment of diphtheria toxin linked to T cell-specific antibody identifies regions of B chain active in cell entry,J. Biol. Chem., 261:3030-3035, 1986.
Dalldorf et al., “The lymphomas of Brazilian children,”J. Am. Med. Assn., 208:1365-1368, 1969.
Deacon et al., “Detection of Epstein-Barr virus antigens and DNA in major and minor salivary glands using immunocytochemistry and polymerase chain reaction: possible relationship with Sjogren's Syndrome,”J. Pathol., 163:351-360, 1991.
Deacon et al., “Frequency of EBV DNA detection in Sjogren's Syndrome,”Am. J. Med., 92:453-454, 1992.
Debrus et al., “Varicella-zoster virus gene 63 encodes an immediate-early protein that is abundantly expressed during latency,”J. Virol., 69:3240-3245, 1995.
Dedrick et al., “Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer,”Cancer Treat Rep., 62:1-11, 1978.
Deleers et al., “Localization in diphtheria toxin fragment B of a region that induces pore formation in planar lipid bilayers at low pH,”FEBS Lett., 160:82-86, 1983.
Diener et al., “Specific immunosuppression by immunotoxins containing daunomycin,”Science, 231:148-150, 1986.
Digard et al., “Functional analysis of the herpes simplex virus UL42 protein,”J. Virol., 67:1159-1168, 1993.
Dittmer et al., “A cluster of latently expressed genes in Kaposi's sarcoma-associated herpes virus,”J. Virol., 72:8309-8315, 1998.
Donahue et al., “The incidence of herpes zoster,”Arch. Int. Med., 155:1605-1609, 1995.
Elek et al., “Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero,”Lancet, 1:1-5, 1974.
Ertl et al., “Physical and functional interation of human cytomegalovirus DNA polymerase and its accessory protein (ICP36) expressed in insect cells,”J. Virol., 66:4126-4133, 1992.
Ferrel et al., “Seroepidemiologial study of relationships between Epstein-Barr virus and rheumatoid arthritis,”J. Clin. Invest., 67:681-687, 1981.
Finerty et al., “Immunization of Cottontop Tamarins and rabbits with a candidate vaccine against the Epstein-Barr virus based on the major viral envelope Glycoprotein gp340 and Alum,”Vaccine, 12:1180-1184, 1994.
Finerty et al., “Protective immunization against Epstein-Barr virus-induced disease in Cottontop Tamarins using the virus envelope glycoprotein gp340 produced fro a Bovine Papillomavirus expression vector,”J. Gen. Virol., 73:449-453, 1992.
Fox et al., “Detection of Epstein-Barr virus-associated antigens in DNA in salivary glands biopsies from patients with Sjogren's Syndrome,”J. Immunol.137:3162-3168, 1986.
Fox et al., “Potential role of Epstein-Barr Virus in Sjogren's Syndrome and Rheumatoid Arthritis,”J. Rheumatol., 19:18-24, 1992.
Fox, “Sjogren's Syndrome,”Current Opin. Rheum., 7:409-416, 1995.
Glassy et al., “Immunodetection of cell-bound antigens using both mouse and human monoclonal antibodies,”J. Immunol. Methods, 81:115, 1985.
Goodrich et al., “Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marros transplant,”Ann. Intern. Med., 118:173-178, 1993.
Gray et al., “Cloning, nucleotide sequence, and expression inEscherichia coliof the exotoxin A structural gene ofPseudomonas aeruginosa,” Proc. Natl. Acad. Sci. USA
Harley John B.
James Judith Ann
Kaufman Kenneth M.
Fulbright & Jaworski LLP
Oklahoma Medical Research Foundation
Salimi Ali R.
LandOfFree
Assays and therapies for latent viral infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assays and therapies for latent viral infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assays and therapies for latent viral infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3993814